BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
일요일, 9월 27

Calidi Biotherapeutics Inc

CLDIAMEX
Trade with Public
Trade with Public
$1.13
-0.07-5.83%
가까이에: Sep 25, 5:00 PM EST
$1.13
N/A
시간외: Sep 25, 7:27 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교주식 보고서

Calidi Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Calidi Biotherapeutics (CLDI).

Price Target Range — 3 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$3200Upside to Avg. PT+283085.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Jun 27, 2024Ladenburg ThalmannAydin HuseynovInitiateBuy$1
May 15, 2024BairdJoel BeattyPT CutOutperform$5→$2
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Ladenburg Thalmann Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $1

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and announces Price Target of $1.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $2

Baird analyst Joel Beatty maintains Calidi Biotherapeutics (AMEX:CLDI) with a Outperform and lowers the price target from $4.5 to $2.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $4.5

Baird analyst Joel Beatty maintains Calidi Biotherapeutics (AMEX:CLDI) with a Outperform and lowers the price target from $9 to $4.5.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Calidi Biotherapeutics, Lowers Price Target to $2

HC Wainwright & Co. analyst Robert Burns maintains Calidi Biotherapeutics (AMEX:CLDI) with a Buy and lowers the price target from $11 to $2.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $11

HC Wainwright & Co. analyst Robert Burns initiates coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and announces Price Target of $11.
Benzinga Newsdesk

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc (NYSE: CLDI), which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment.
Vandana Singh

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved